Clinical trial
A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for…
NCT00472758 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00472758 |
|---|---|
| Title | A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 |
| Official title | A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis |
| Acronym | CP145 |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Plaque Psoriasis |
| Intervention type | Biological, Other |
| Interventions | MEDI 545, Placebo |
| Enrollment | 40 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 14, 2007 |
| Last update posted | Nov 17, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: